Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS

Drug Safety

Volumn 40, Issue 5, 2017, Pages 399-408

  Colilla, Susan ^a   Tov, Elad Yom ^b   Zhang, Ling ^a   Kurzinger, Marie Laure ^a   Tcherny Lessenot, Stephanie ^a   Penfornis, Catherine ^a   Jen, Shang ^c   Gonzalez, Danny S ^d   Caubel, Patrick ^e   Welsh, Susan ^a   Juhaeri, Juhaeri ^a  

^a SANOFI   (France)

^b MICROSOFT RESEARCH   (United States)

^c Baxalta US   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; DATA BASE; FALSE POSITIVE RESULT; FDA ADVERSE EVENT REPORTING SYSTEM; PRIORITY JOURNAL; PROPORTIONAL QUERY RATE RATIO; PROPORTIONAL QUERY RATIO; SEARCH ENGINE; SIGNAL DETECTION; VALIDATION STUDY; WEB QUERY LOG DATA; ADVERSE DRUG REACTION; COMPARATIVE STUDY; DATA MINING; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNET; POSTMARKETING SURVEILLANCE; PROCEDURES; TIME FACTOR; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATA MINING; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERNET; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85011709977     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-017-0507-4     Document Type: Article

References (21)

1. Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015;54:202–12.
2. Fletcher AP. An appraisal of spontaneous adverse event monitoring. Adverse Drug React Toxicol Rev. 1992;11(4):213–27.
3. Harpaz R, Callahan A, Tamang S, Low Y, Odgers D, Finlayson S, et al. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014;37(10):777–90.
4. Morel P, Vandel B. Adverse drug reaction monitoring and the Internet: evaluation of the use of the Internet by French Pharmacovigilance Centres and a non-exhaustive survey of websites of interest for collecting information about adverse drug reaction. Therapie. 1999;54(5):525–32.
5. White RW, Harpaz R, Shah NH, DuMouchel W, Horvitz E. Toward enhanced pharmacovigilance using patient-generated data on the internet. Clin Pharmacol Ther. 2014;96(2):239–46.
6. Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: a review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80(4):910–20.
7. Yom-Tov E, Gabrilovich E. Postmarket drug surveillance without trial costs: discovery of adverse drug reactions through large-scale analysis of web search queries. J Med Internet Res. 2013;15(6):e124.
8. Yang M, Kiang M, Shang W. Filtering big data from social media–Building an early warning system for adverse drug reactions. J Biomed Inform. 2015;54:230–40.
9. Dal Pan G, editor. Adverse event reporting and medication safety considerations: a view from CDER’s Office of Surveillance and Epidemiology. CHPA Regulatory, Scientific, and Quality Conference: Washington, DC; 2013.
10. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for industry. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines. Rockville: US Department of Health and Human Services; 2001.
11. Odgers DJ, Harpaz R, Callahan A, Stiglic G, Shah NH. Analyzing search behavior of healthcare professionals for drug safety surveillance. Pac Symp Biocomput. 2015:306–17.
12. Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf. 2006;29(10):875–87.
13. Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–92.
14. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–46.
15. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.
16. Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, et al. Social media listening for routine post-marketing safety surveillance. Drug Saf. 2016;39(5):443–54.
17. Austin PC, Steyerberg EW. Interpreting the concordance statistic of a logistic regression model: relation to the variance and odds ratio of a continuous explanatory variable. BMC Med Res Methodol. 2012;12:82.
18. Sarntivijai S, Abernethy DR. Use of internet search logs to evaluate potential drug adverse events. Clin Pharmacol Ther. 2014;96(2):149–50.
19. DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36(Suppl 1):S123–32.
20. Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413–9.
21. Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577–87.